Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|September 1, 2002
IPO positions Alcon for tomorrow
Author(s)Mark L. Dlugoss
Fort Worth, TX-Amid the fanfare of the New York Stock Exchange and company executives, Tim Sear of Alcon Laboratories Inc. and Peter Brabeck-Letmathe of Nestl? A stood atop the balcony overlooking the trading floor and rang the opening bell, marking the official start of the day on Wall Street.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Tenpoint Therapeutics opens telehealth access to Yuvezzi for adults with presbyopia
2
Longer anti-VEGF intervals in AMD, BRVO, and DME: 3 clinical cases
3
City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease
4
The interplay between cardiac disease and the eye
5